Food and Drug
Administration
CENTER FOR DRUG EVALUATION AND RESEARCH
(CDER)
Cardiovascular and Renal Drugs Advisory
Committee
Hilton Washington DC
North/Gaithersburg
Gaithersburg Maryland
SLIDES
April 25, 2006
The
committee will discuss
new drug application (NDA) 21-359 Cellegesic™ (nitroglycerin
[NTG] ointment), 0.4% intra-anal, Cellegy Pharmaceuticals,
Inc., for the proposed indication of relief of pain associated
with anal fissures
Sponsor Presentation – Cellegy Pharmaceuticals,
Inc:
FDA
Presentation:
Up
| AC Home Page